Arsenic trioxide induces apoptosis of Burkitt lymphoma cell lines through multiple apoptotic pathways and triggers antiangiogenesis

Oncology Research

Volumn 19, Issue 3-4, 2011, Pages 149-163

  Li, Hui Min ^a   Long, Yi ^a   Qing, Chen ^a   Yu, Meijia ^a   Li, Zhi Hui ^a,b   Zhang, Xue Mei ^a   Li, Xiao Jin ^a   Chen, Ya Juan ^a   Zhang, Yan Li ^a   Liang, Yang ^c  

^a KUNMING MEDICAL UNIVERSITY   (China)

^b Dao Pei Hospital   (China)

^c KUNMING GENERAL HOSPITAL   (China)

Author keywords

Arsenic trioxide; Bcl 2; Burkitt lymphoma; MCL 1; Survivin; VEGF

Indexed keywords

ARSENIC TRIOXIDE; PROTEIN BCL 2; PROTEIN MCL 1; SURVIVIN; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; BURKITT LYMPHOMA; CELL CYCLE ARREST; CONTROLLED STUDY; HUMAN; HUMAN CELL; LYMPHOMA CELL LINE; MEMBRANE POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY FUNCTION;

EID: 79952429308     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504011X12935427587885     Document Type: Article

References (34)

1. Burkitt, D. A sarcoma involving the jaws in African children. Br. J. Surg. 46:218-223; 1958.
2. Stiller, C. A.; Parkin, D. M. International variations in the incidence of childhood lymphomas. Pediatr. Perinat. Epidemiol. 4:303-324; 1990.
3. Mbulaiteye, S. M.; Biggar, R. J.; Bhatia, K. Linet, M. S.; Devesa, S. S. Sporadic childhood Burkitt lymphoma incidence in the United States during 1992-2005. Pediatr. Blood Cancer 53:366-370; 2009.
4. Levine, P. H.; Kamaraju, L. S.; Connelly, R. R.; Berard, C. W.; Dorfman, R. F.; Magrath, I.; Easton, J. M. The American Burkitt's Lymphoma Registry: Eight years' experience. Cancer 49:1016-1022; 1982.
5. Brady, G.; MacArthur, G. J.; Farrell, P. J. Epstein-Barr virus and Burkitt lymphoma. J. Clin. Pathol. 60:1397-1402; 2007.
6. Thorley-Lawson, D. A.; Gross, A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N. Engl. J. Med. 350:1328-1337; 2004.
7. de-The, G.; Geser, A.; Day, N. E.; Tukei, P. M.; Williams, E. H.; Beri, D. P.; Smith, P. G.; Dean, A. G.; Bronkamm, G. W.; Feorino, P.; Henle, W. Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study. Nature 274:756-761; 1978.
8. Rochford, R.; Cannon, M. J.; Moormann, A. M. Endemic Burkitt's lymphoma: A polymicrobial disease. Nat. Rev. Microbiol. 3:182-187; 2005.
9. Cairo, M. S.; Gerrard, M.; Sposto, R. Auperin, A.; Pinker ton, C. R.; Michon, J.; Weston, C.; Perkins, S. L.; Raphael, M.; McCarthy, K.; Patte, C.; FAB LMB96 International Study Committee. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 109:2736-2743; 2007.
10. Patte, C.; Auperin, A.; Gerrard, M.; Michon, J. Pinkerton, R.; Sposto, R.; Weston, C.; Raphael, M.; Perkins, S. L.; McCarthy, K.; Cairo, M. S.; FAB/LMB96 International Study Committee. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: It is possible to reduce treatment for the early responding patients. Blood 109:2773-2780; 2007.
11. O'Dwyer, M. E.; La Rosee, P.; Nimmanapalli, R.; Bhalla, K. N.; Druker, B. J. Recent advances in Philadelphia chromosome-positive malignancies: The potential role of arsenic trioxide. Semin. Hematol. 39(Suppl. 1):18-21; 2002.
12. Chen, G. Q.; Shi, X. G.; Tang, W. Xiong, S. M.; Zhu, J.; Cai, X.; Han, Z. G.; Ni, J. H.; Shi, G. Y.; Jia, P. M.; Liu, M. M.; He, K. L.; Niu, C.; Ma, J.; Zhang, P.; Zhang, T. D.; Paul, P.; Naoe, T.; Kitamura, K.; Miller, W.; Waxman, S.; Wang, Z. Y.; de The, H.; Chen, S. J.; Chen, Z. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL), I: ATO exerts dose-dependent dual effects on APL cells. Blood 89:3345-3353; 1997.
13. Shen, Z. X.; Chen, G. Q.; Ni, J. H.; Li, X. S.; Xiong, S. M.; Qiu, Q. Y.; Zhu, J.; Tang, W.; Sun, G. L.; Yang, K. Q.; Chen, Y.; Zhou, L.; Fang, Z. W.; Wang, Y. T.; Ma, J.; Zhang, P.; Zhang, T. D.; Chen, S. J.; Chen, Z.; Wang, Z. Y. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL), II: Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89:3354- 3360; 1997.
14. Soignet, S. L.; Maslak, P.; Wang, Z. G.; Jhanwar, S.; Calleja, E.; Dardashti, L. J.; Corso, D.; DeBlasio, A.; Gabrilove, J.; Scheinberg, D. A.; Pandolfi, P. P.; Warrell, Jr., R. P. Complete remission after treatment of acute pro- myelocytic leukemia with arsenic trioxide. N. Engl. J. Med. 339:1341-1348; 1998.
15. Wang, L.; Zhou, G. B.; Liu, P.; Song, J. H.; Liang, Y.; Yan, X. J.; Xu, F.; Wang, B. S.; Mao, J. H.; Shen, Z. X.; Chen, S. J.; Chen, Z. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an ef- fective treatment for promyelocytic leukemia. Proc. Natl. Acad. Sci. USA 105:4826-4831; 2008.
16. Ito, K.; Bernardi, R.; Morotti, A.; Matsuoka, S.; Saglio, G.; Ikeda, Y.; Rosenblatt, J.; Avigan, D. E.; Teruya-Feld- stein, J.; Pandolfi, P. P. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 453:1072-1078; 2008
17. Madesh, M.; Bhaskar, L.; Balasubramanian, K. A. Entero- cyte viability and mitochondrial function after graded intestinal ischemia and reperfusion in rats. Mol. Cell. Bio- chem. 167:81-87; 1997;
18. Mathews, V.; Balasubramanian, P.; Shaji, R. V.; George, B.; Chandy, M.; Srivastava, A. Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: A single center experience. Am. J. Hematol. 70:292-299; 2002.
19. Zhu, X. H.; Shen, Y. L.; Jing, Y. K.; Cai, X.; Jia, P. M.; Huang, Y.; Tang, W.; Shi, G. Y.; Sun, Y. P.; Dai, J.; Wang, Z. Y.; Chen, S. J.; Zhang, T. D.; Waxman, S.; Chen, Z.; Chen, G. Q. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J. Natl. Cancer Inst. 91:772-778; 1999.
20. Zhang, W.; Ohnishi, K.; Shigeno, K. Fujisawa, S.; Naito, K.; Nakamura, S.; Takeshita, K.; Takeshita, A.; Ohno, R. The induction of apoptosis and cell arrays by arsenic trioxide in lymphoid neoplasms. Leukemia 12:1383-1391; 1998.
21. He, Y.; Yang, J. M.; Wang, J. M.; Zhou, H.; Lü, S. Q.; Hu, X. X. Synergistic effects of arsenic trioxide and proteasome inhibitor bortezomib on apoptosis induction in Raji cell line. Zhongguo Shi Yan Xue Ye Xue Za Zhi 16: 794-798; 2008.
22. Lu, D.; Bai, X. C.; Gui, L.; Su, Y. C.; Deng, F.; Liu, B.; Li, X. M.; Zeng, W. S.; Cheng, B. L.; Luo, S. Q. Hydrogen peroxide in the Burkitt's lymphoma cell line Raji pro- vides protection against arsenic trioxide-induced apoptosis via the phosphoinositide-3 kinase signalling pathway. Br. J. Haematol. 125:512-520; 2004.
23. Muscarella, D. E.; Bloom, S. E. Differential activation of the c-Jun N-terminal kinase pathway in arsenite-induced apoptosis and sensitization of chemically resistant compared to susceptible B-lymphoma cell lines. Toxicol. Sci. 68:82-92; 2002.
24. Shen, L.; Chen, T. X.; Wang, Y. P.; Lin, Z.; Zhao, H. J.; Zu, Y. Z.; Wu, G.; Ying, D. M. As2O3 induces apoptosis of the human B lymphoma cell line MBC-1. J. Biol. Regul. Homeost. Agents 14:116-119; 2000.
25. Ravandi, F.; van Besien, K. Clinical activity of arsenic trioxide in Burkitt-like lymphoma. Leukemia 17:271-272; 2003.
26. Zhu, X. H.; Shen, Y. L.; Jing, Y. K.; Cai, X.; Jia, P. M.; Huang, Y.; Tang, W.; Shi, G. Y.; Sun, Y. P.; Dai, J.; Wang, Z. Y.; Chen, S. J.; Zhang, T. D.; Waxman, S.; Chen, Z.; Chen, G. Q. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J. Natl. Cancer Inst. 91:772-778; 1999.
27. Zhu, J.; Okumura, H.; Ohtake, S.; Nakamura, S.; Nakao, S. The molecular mechanism of arsenic trioxide-induced apoplosis and oncosis in leukemia/lymphoma cell lines. Acta Haematol. 110:1-10; 2003.
28. Chen, G. Q.; Zhu, J.; Shi, X. G.; Ni, J. H.; Zhong, H. J.; Si, G. Y.; Jin, X. L.; Tang, W.; Li, X. S.; Xong, S. M.; Shen, Z. X.; Sun, G. L.; Ma, J.; Zhang, P.; Zhang, T. D.; Gazin, C.; Naoe, T.; Chen, S. J.; Wang, Z. Y.; Chen, Z. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induce NB4 cell apoptosis with downregulation of BCL-2 expression and modulation of PML/RARa alpha/PML proteins. Blood 88:1052-1061; 1996.
29. Cai, X.; Shen, Y. L.; Zhu, Q.; Jia, P. M.; Yu, Y.; Zhou, L.; Huang, Y.; Zhang, J. W.; Xiong, S. M.; Chen, S. J.; Wang, Z. Y.; Chen, Z.; Chen, G. Q. Arsenic trioxide- induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 14:262-270; 2000.
30. Ambrosini, G.; Adida, C.; Altierc, D. C. A novel anliapoptosis gene, Survivin, expressed in cancer and lymphoma. Nat. Med. 3:917-921; 1997.
31. Folkman, J. Incipient angiogenesis. J. Natl. Cancer Inst. 92:94-95; 2000.
32. Tischer, E.; Mitchell, R.; Hartman, T.; Silva, M.; Gospodarowicz, D.; Fiddes, J.; Abraham, J. The human gene for vascular endothelial growth factor. J. Biol. Chem. 266: 11947-11954; 1991.
33. Keyt, B. A.; Berleau, L. T.; Nguyen, H. V.; Chen, H.; Heinsohn, H.; Vandlen, R.; Ferrara, N. The carboxylterminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J. Biol. Chem. 271:7788-7795; 1996.
34. Roboz, G. J.; Dias, S.; Lam, G.; Lane, W. J.; Soignet, S. L.; Warrell, Jr., R. P.; Rafii, S. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 96:1525-1530; 2000.